AnthonyGeorgeLetaiMD

PubMed

• 236 citations
  Mitochondria-Judges and Executioners of Cell Death Sentences.
  Patrick Bhola, Anthony Letai
  Molecular Cell. 2016-03-03
• 180 citations
  BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response
  Kristopher A. Sarosiek, Xiaoke Chi, John A. Bachman, Joshua J. Sims, Joan Montero
  Molecular Cell. 2013-09-26
• 1124 citations
  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
  Rumani Singh, Anthony Letai, Kristopher A. Sarosiek
  Nature Reviews. Molecular Cell Biology. 2019-03-01

Journal Articles

• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia  
  Courtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
• Targeted Inhibition of PI3Kα/Δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL  
  Anthony Letai, Margaret A Shipp, Blood
• PPM1D Truncating Mutations Confer Resistance to Chemotherapy and Sensitivity to PPM1D Inhibition in Hematopoietic Cells  
  Peter G Miller, Brenton Mar, Benjamin L Ebert, Shaunt Fereshetian, Anthony Letai, Siddhartha Jaiswal, Blood
• BCL-2 Inhibition in AML - an Unexpected Bonus?  
  Marina Konopleva, Anthony Letai, Blood
• Join now to see all

Abstracts/Posters

• Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
  Anthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
  Anthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
  Anthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre...
  Anthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant Abstract
  Anthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
  Anthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL
  Anthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018